Celladon, which is developing novel therapies for the treatment of heart disease, revived its IPO by filing an amended S-1 with the SEC on Wednesday. The company had previously launched a deal to sell 5 million shares at $14 to $16 per share but postponed on November 13. The company's updated filing removed the original IPO terms. The San Diego, CA-based company, which was founded in 2000, plans to list on the NASDAQ under the symbol CLDN. Barclays is the sole bookrunner on the deal.
